Partnering Strategy

Starpharma adopts a partnering strategy in which, usually after proof of concept by Starpharma, one or more sector-leading partners are identified with the expertise and resources to advance products to market.

 

The partner-led approach helps to ensure that Starpharma can remain focused on its core “platform” competencies whilst maximizing the opportunities for commercialization of the technology.

 

Starpharma’s commercialising partners include:

  • Ansell
  • Okamoto
  • Lilly
  • Elanco
  • GSK’s Stiefel Laboratories Inc
  • Siemens Healthcare
  • Qiagen
  • EMD Merck
  • (unnamed) billion dollar US agrochemicals company
  • Sigma-Aldrich

 

Contact Us if you are interested in establishing a partnership with Starpharma.

 

 

 

 


© Starpharma Holdings Limited 2012